Table 1 Characteristics of included patients with valid SAMHD1 data

From: Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

 

Total

MDACC

Singapore

P

Number of included patients

189

87

102

 

Age (years), median (range)

52 (18–80)

56 (18–79)

48 (19–80)

0.054a

SAMHD1 percent positive blasts, median (range)

30 (1–100)

40 (3–100)

25 (1–95)

0.021a

Male sex, n (%)

103 (54.5)

50 (57.5)

53 (52.0)

0.47d

Cytogenetic risk group

<0.0001b

Favorable, n (%)

12 (6.3)

0 (0.0)

12 (11.8)

 

Intermediate, n (%)

157 (83.1)

87 (100.0)

70 (68.6)

 

Poor, n (%)

19 (10.1)

0 (0.0)

19 (18.6)

 

N/A, n (%)

1 (0.5)

0 (0.0)

1 (1.0)

 

Response

<0.0001b

Complete response, n (%)

106 (56.1)

74 (85.1)

32 (31.4)

 

No complete response, n (%)

68 (36.0)

11 (12.6)

57 (55.9)

 

N/A, n (%)

15 (7.9)

2 (2.3)

13 (12.7)

 

FLT3-ITD mutation

0.56b

Positive, n (%)

45 (23.8)

32 (36.8)

13 (12.7)

 

Negative, n (%)

84 (44.4)

54 (62.1)

30 (29.4)

 

N/A, n (%)

60 (31.7)

1 (1.1)

59 (57.8)

 

FLT3-TKD mutation

0.17b

Positive, n (%)

11 (5.8)

10 (11.5)

1 (1.0)

 

Negative, n (%)

115 (60.8)

76 (87.4)

39 (38.2)

 

N/A, n (%)

63 (33.3)

1 (1.1)

62 (60.8)

 

NPM1 mutation

0.0075b

Positive, n (%)

44 (23.3)

38 (43.7)

6 (5.9)

 

Negative, n (%)

60 (31.7)

37 (42.5)

23 (22.5)

 

N/A, n (%)

85 (45.0)

12 (13.8)

73 (71.6)

 

IDH mutation

Positive, n (%)

11 (5.8)

0 (0.0)

11 (10.8)

 

Negative, n (%)

37 (19.6)

0 (0.0)

37 (36.3)

 

N/A, n (%)

141 (74.6)

87 (100.0)

54 (52.9)

 

DNMT3A mutation

Positive, n (%)

10 (5.3)

0 (0.0)

10 (9.8)

 

Negative, n (%)

39 (20.6)

0 (0.0)

39 (38.2)

 

N/A, n (%)

140 (74.1)

87 (100.0)

53 (52.0)

 

Induction treatment

   

<0.0001c

High-dose AraC

89 (47.1)

87 (100.0)

2 (2.0)

 

Low-dose AraC

55 (29.1)

0 (0.0)

55 (53.9)

 

Other/N/A, n (%)

45 (23.8)

0 (0.0)

45 (44.1)

 

Consolidation treatment

   

<0.0001d

High-dose AraC

119 (63.0)

87 (100.0)

32 (31.4)

 

Other/N/A, n (%)

70 (37.0)

0 (0.0)

70 (68.6)

 

Clofarabine

Yes, n (%)

23 (12.2)

23 (26.4)

0 (0.0)

 

No, n (%)

64 (33.9)

64 (73.6)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 

Fludarabine

Yes, n (%)

25 (13.2)

25 (28.7)

0 (0.0)

 

No, n (%)

62 (32.8)

62 (71.3)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 

Cladribine

Yes, n (%)

2 (1.1)

2 (2.3)

0 (0.0)

 

No, n (%)

85 (45.0)

85 (97.7)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 

Sorafenib

Yes, n (%)

6 (3.2)

6 (6.9)

0 (0.0)

 

No, n (%)

81 (42.9)

81 (93.1)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 

Gemtuzumab-ozogamicin

Yes, n (%)

6 (3.2)

6 (6.9)

0 (0.0)

 

No, n (%)

81 (42.9)

81 (93.1)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 

Vorinostat (SAHA)

Yes, n (%)

12 (6.3)

12 (13.8)

0 (0.0)

 

No, n (%)

75 (39.7)

75 (86.2)

0 (0.0)

 

N/A, n (%)

102 (54.0)

0 (0.0)

102 (100.0)

 
  1. aMann–Whitney U-test
  2. bFisher’s exact test (excluding N/A category)
  3. cChi-square test
  4. dFisher’s exact test
Back to article page